Calotatug ginistinag
Based on 1 Customer Validation
Calotatug ginistinag (XMT-2056) is an antibody-drug conjugate (ADC) targeting HER2, linked to a payload composed of XMT-1519 conjugate-1 (HY-148067) and STING agonist-20 (HY-148068). Calotatug ginistinag activates the STING signaling pathway in tumor cells and tumor-resident immune cells, induces the production of type I interferons and cytokines (CXCL10, IFN-β, IL-6, TNF-α, triggers innate anti-tumor immune responses, and exerts a bystander effect. Calotatug ginistinag exhibits efficacy against HER2-expressing cancer cells in co-culture with PBMCs. Calotatug ginistinag induces tumor regression and reduces systemic inflammation in various tumor models. Combination treatment with Calotatug ginistinag, Trastuzumab (HY-P9907) and T-DXd (HY-138298) yields benefits. Calotatug ginistinag can be used in studies related to HER2-expressing solid tumors such as breast cancer, gastric cancer and ovarian cancer.
For research use only. We do not sell to patients.
- Purity : 95.94%
- CAS No.: 2847102-44-5
-
Storage:
-80°C, protect from light
All EGFR Isoforms
More
Biological Activity
Description
IC50 & Target
|
HER2 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MDA-MB-175-VII | IC50 |
0.38 nM
|
Immune-mediated killing of human MDA-MB-175-VII-NR HER2-low breast cancer cells in PBMC cocultures, with 20 minutes pre-incubation with MDA-MB-175-VII-NR cells and 84 hours total incubation, quantified via live-cell imaging of red fluorescence.
Immune-mediated killing of human MDA-MB-175-VII-NR HER2-low breast cancer cells in PBMC cocultures, with 20 minutes pre-incubation with MDA-MB-175-VII-NR cells and 84 hours total incubation, quantified via live-cell imaging of red fluorescence.
|
40029253 |
In Vitro
Calotatug ginistinag induces cytokine production and kills cancer cells in PBMC co-culture systems with cancer cells that have low HER2 expression[1].
Calotatug ginistinag (24 h) directly activates STING in HER2-positive HCC1954 breast cancer cells and induces CXCL10 production, with an EC50 of 2.67 nM payload[2].
Calotatug ginistinag (24 h) induces antigen-dependent, Fcγ receptor-mediated STING activation in THP1 monocytes when co-cultured with HER2-positive SKOV3 ovarian cancer cells[2].
Calotatug ginistinag (24 h) induces antigen-dependent, Fcγ receptor-mediated STING activation in THP1 monocytes cultured on recombinant HER2 protein-coated plates[2].
Calotatug ginistinag (0.01-1000 nM payload; 84 h) potently induces immune-mediated killing of HER2-positive SKBR3-NR breast cancer cells in a PBMC co-culture system, with an IC50 of 0.023 nM for its payload[2].
Calotatug ginistinag (0.01-1000 nM payload; 84 h) induces immune-mediated killing of HER2-low expressing MDA-MB-175-VII-NR breast cancer cells in a PBMC co-culture system, with an IC50 of 0.38 nM for its payload[2].
Calotatug ginistinag (0.01-10 nM payload; 84 h) induces immune-mediated killing of HER2-negative MDA-MB-231-NR breast cancer cells, and this effect occurs only in the presence of HER2-positive SKBR3 breast cancer cells and peripheral blood mononuclear cells (PBMCs). The IC50 value of its payload is 0.25 nM at a 1:1 ratio and 0.34 nM at a 1:4 ratio[2].
Calotatug ginistinag (0.01-1000 nM payload; 24 h) induces concentration-dependent production of STING pathway cytokines (CXCL10, IFN-β, IL-6, TNF-α) in a co-culture system of SKBR3-NR breast cancer cells and PBMCs, with EC50 values of the payload ranging from 0.17 to 0.46 nM[2].
Calotatug ginistinag (0.01-1000 nM payload; 24 h) induces concentration-dependent expression of STING pathway cytokines (CXCL10, IFN-β, IL-6, TNF-α) in a co-culture system of MDA-MB-175-VII-NR breast cancer cells and PBMCs, with EC50 values of the payload ranging from 0.30 to 0.76 nM[2].
Calotatug ginistinag specifically binds to HER2-positive HCC1954 breast cancer cells, with a binding affinity comparable to that of unconjugated HT19 antibody[2].
Calotatug ginistinag specifically binds to HER2-positive SKOV3 ovarian cancer cells, with a binding affinity comparable to that of the unconjugated HT19 antibody and the Fc mutant XMT-2056[2].
Calotatug ginistinag binds to Fcγ-RI, whereas the Fc mutant XMT-2056 lacks Fcγ-RI binding activity[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
Calotatug ginistinag (1-3 mg/kg; intravenous injection; single administration) induces complete and sustained tumor regression in HER2-expressing HCC1954 and SNU-5 xenograft models, with superior efficacy to free STING agonists[2].
Calotatug ginistinag (0.2 mg/kg; intravenous injection; single administration) enhances the anti-tumor activity of Trastuzumab (HY-P9907) in SNU-5 xenografts[2].
Calotatug ginistinag (1-3 mg/kg; intravenous injection; single administration) induces tumor growth delay in Trastuzumab-resistant JIMT-1 xenografts, with better efficacy than free STING agonists[2].
Calotatug ginistinag (0.2 mg/kg; intravenous injection; once weekly; 3 doses total) enhances the anti-tumor activity of Trastuzumab in SKOV3 xenografts[2].
Combination of calotatug ginistinag (1 mg/kg; intravenous injection; single dose) with T-DXd (HY-138298) induces durable tumor regression in a Trastuzumab-resistant JIMT-1 breast cancer xenograft model[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:CB.17 SCID (female; subcutaneous inoculation with 1×107 SKOV3 cells in 50% Matrigel)[2]
-
Dosage:Single agent (single dose): 0.3 mg/kg, 1 mg/kg, 3 mg/kg;
Single agent (weekly × 3): 0.067 mg/kg, 0.17 mg/kg, 0.3 mg/kg;
Trastuzumab (weekly × 3): the ADC 0.2 mg/kg + Trastuzumab 2 mg/kg -
Administration:Single agent (single dose): Intravenous injection (i.v.); single dose; Single agent (weekly × 3): Intravenous injection (i.v.); weekly × 3 doses; Trastuzumab: the ADC: Intravenous injection (i.v.), weekly × 3 doses; Trastuzumab: Intraperitoneal injection (i.p.), weekly × 3 doses
-
Result:Induced complete and sustained tumor regressions with a single 1 mg/kg or 3 mg/kg dose.
Resulted in partial and complete responses with three weekly 0.067 mg/kg doses.
Activated STING pathway in both tumor cells and murine host cells with a single 0.3 mg/kg dose.
Induced transient elevations in serum cytokines (CXCL10, IL-6, MIP-1β, RANTES, CXCL9), which were 1.5- to 10-fold lower than those induced by a free diABZI STING agonist.
Elevated murine mRNA levels of immune cell markers CD68 and CD45 in tumors 72 hours post-treatment.
Increased tumor infiltration of CD68+ and CD45+ cells.
Upregulated mPD-L1 staining.
Showed improved antitumor activity in combination with trastuzumab over either single agent.
-
Animal Model:SCID beige (female; subcutaneous inoculation with 1×107 HCC1954 cells in 50% Matrigel)[2]
-
Dosage:1 mg/kg (single dose); 3 mg/kg (single dose)
-
Administration:i.v.; single dose
-
Result:Induced complete and sustained tumor regressions with a single 1 mg/kg or 3 mg/kg dose.
Outperformed a free diABZI STING agonist administered at a 100-fold higher payload dose equivalent.
-
Animal Model:CB.17 SCID (female; subcutaneous inoculation with 1×107 SNU-5 cells in 50% Matrigel)[2]
-
Dosage:Single agent: 1 mg/kg, 3 mg/kg; Trastuzumab: the ADC 0.2 mg/kg + Trastuzumab 2 mg/kg
-
Administration:Single agent: Intravenous injection (i.v.); single dose; Trastuzumab: the ADC: Intravenous injection (i.v.), single dose; Trastuzumab: Intraperitoneal injection (i.p.), single dose
-
Result:Induced complete and sustained tumor regressions with a single 1 mg/kg or 3 mg/kg dose.
Outperformed a free diABZI STING agonist administered at a 100-fold higher payload dose equivalent.\nShowed improved antitumor activity in combination with trastuzumab over either single agent.
-
Animal Model:CB.17 SCID (female; subcutaneous inoculation with 1×107 JIMT-1 cells in 50% Matrigel)[2]
-
Dosage:Single agent: 1 mg/kg, 3 mg/kg; the ADC 0.3 mg/kg + Trastuzumab 3 mg/kg; the ADC 1 mg/kg + T-DXd 3 mg/kg
-
Administration:Single agent: Intravenous injection (i.v.); single dose
Trastuzumab: the ADC: Intravenous injection (i.v.), weekly × 3 doses; Trastuzumab: Intraperitoneal injection (i.p.), weekly × 3 doses
T-DXd: the ADC: Intravenous injection (i.v.), single dose; T-DXd: Intravenous injection (i.v.), weekly × 2 doses (1 week apart) -
Result:Showed improved antitumor activity in combination with trastuzumab over either single agent.
Induced durable tumor regressions when 3 mg/kg XMT-2056 was combined with trastuzumab deruxtecan (T-Dxd).
Induced tumor growth delay with a single 1 mg/kg or 3 mg/kg dose.
Outperformed a free diABZI STING agonist administered at a 100-fold higher payload dose equivalent.
Chemical Information
-
CAS No. 2847102-44-5
-
Appearance Liquid
-
Color Colorless to light yellow
-
SMILES
[Calotatug ginistinag]
-
Synonyms
XMT-2056
-
Shipping
Shipping with dry ice.
-
Storage
-80°C, protect from light
Protocols
-
LPS-Induced Endotoxemia/Systemic Inflammation
Lipopolysaccharide (LPS)-induced endotoxemia is a widely used in vivo model of acute systemic inflammation in which LPS, a Gram-negative bacterial endotoxin, activates innate immune signaling primarily through TLR4, leading to rapid and transient induction of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β in circulation and tissues. This cytokine surge is commonly used as a measurable readout of systemic inflammatory activation and immune dysregulation, and is typically assessed within hours after intraperitoneal LPS administration in mouse models of endotoxemia. The model captures key features of systemic inflammatory response syndrome, including cytokine release, immune cell activation, and downstream tissue responses, and has been used to evaluate anti-inflammatory interventions such as cytokine modulation, lipid mediators, and immune cell-targeting therapies.
-
Neuron-Astrocyte Co-culture
Neuron-astrocyte co-culture is used to study how astrocytes regulate neuronal survival, synapse formation, dendritic morphology, neuronal activity, and disease-related neurotoxicity. Indirect “sandwich” or insert-based designs physically separate neurons and astrocytes while allowing soluble astrocyte-derived factors to affect neurons, whereas direct co-culture permits cell-contact and network-level readouts.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
Purity & Documentation
-
Data Sheet (285 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[2]. Bukhalid RA, et al. XMT-2056, a HER2-Directed STING Agonist Antibody-Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells. Clinical cancer research : an official journal of the American Association for Cancer Research. 2025 May 01;31(9):1766-1782. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- Calotatug ginistinag
- 2847102-44-5
- XMT-2056
- XMT2056
- XMT 2056
- Antibody-Drug Conjugates (ADCs)
- EGFR
- STING
- IFNAR
- TNF Receptor
- Interleukin Related
- CXCR
- THP1 monocytes
- PD-L1
- Fcγ receptor
- SKOV3 ovarian cancer cells
- SKBR3-NR breast cancer cells
- PBMC
- HCC1954 breast cancer cells
- MDA-MB-175-VII-NR breast cancer cells
- HER2
- Inhibitor
- inhibitor
- inhibit